History of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXAble to swallow orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or small bowelXx_NEWLINE_xXActive gastrointestinal disease or other malabsorption syndromesXx_NEWLINE_xXGastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent (e.g. intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).Xx_NEWLINE_xXPatients must be able to tolerate oral medications by mouth, and not have a gastrointestinal illness that would preclude absorption of olaparibXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXPresence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of pazopanibXx_NEWLINE_xXMalabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228)Xx_NEWLINE_xXPatients must not have malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinibXx_NEWLINE_xXPatients must be able to take oral medications (i.e., swallow pills whole); patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligibleXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXPatients with known manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228) are INELIGIBLEXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowingXx_NEWLINE_xXCurrent evidence of any of the following:\r\n* Known gastrointestinal disorder affecting absorption of oral medications\r\n* Active uncontrolled infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) \r\n* Uncontrolled hypertension\r\n* Any current condition that in the opinion of the investigator, would preclude participation in this studyXx_NEWLINE_xXPatients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligibleXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac diseaseXx_NEWLINE_xXGastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinibXx_NEWLINE_xXParticipants unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXMalabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXAny malabsorption problem that, in the investigator's opinion, would prevent adequate absorption of the study drugXx_NEWLINE_xXPatients must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients with clinically significant gastrointestinal abnormalities that may affect absorption of the investigational product are NOT eligible for participation; these may include (but are not limited to):\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXGastrointestinal disease known to interfere with absorptionXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXHistory of malabsorption or other clinically significant metabolic dysfunction that may interfere with absorption of oral study treatmentXx_NEWLINE_xXAny gastrointestinal (GI) disorder that may affect absorption of oral medications in the opinion of the treating investigator, such as malabsorption syndrome or major bowel or stomach resectionXx_NEWLINE_xXHistory of malabsorption or other condition that would interfere with absorption of study drugsXx_NEWLINE_xXGastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.Xx_NEWLINE_xXGastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of the study drug.Xx_NEWLINE_xXMajor surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorptionXx_NEWLINE_xXPre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparibXx_NEWLINE_xXInability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedureXx_NEWLINE_xXInability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of BGB-290, which is an oral agent.Xx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128Xx_NEWLINE_xXIncidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.Xx_NEWLINE_xXPatients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g. malabsorption, gastric or small bowel resection, etc.) deemed to jeopardize intestinal absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowingXx_NEWLINE_xXMust not have a gastrointestinal condition that would interfere with absorptionXx_NEWLINE_xXPatients who have a known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing are not eligibleXx_NEWLINE_xXMalabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugsXx_NEWLINE_xXGastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation, active peptic ulcer or prior surgical procedures or bowel resection affecting absorptionXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXUnable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI function that could interfere with absorption of study treatmentXx_NEWLINE_xXAble to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHas gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the Investigator.Xx_NEWLINE_xXInability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedureXx_NEWLINE_xXAble to swallow and retain orally administered medication; does not have any clinically significant gastrointestinal abnormalities, such as malabsorption syndrome or major resection of the stomach or small bowel that may alter absorption of the medicationXx_NEWLINE_xXAny condition that impairs patient’s ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)Xx_NEWLINE_xXSignificant or recent gastrointestinal disorders with diarrhea as a major symptom (e.g. Crohn's disease, malabsorption, or complete blood count [CBC] grade >= 2 diarrhea of any etiology)Xx_NEWLINE_xXAny dysphagia, odynophagia, esophageal dysmotility or stricture, known GI malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of any of the components of SM-88, e.g., cirrhosis.Xx_NEWLINE_xXGastrointestinal (GI) condition which could impair absorption of study medication or inability to ingest study medicationXx_NEWLINE_xXDuodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparibXx_NEWLINE_xXActive gastrointestinal (GI) conditions and uncontrolled irritable bowel disease or pre-existing GI disorders that may interfere with proper absorption of the study drugXx_NEWLINE_xXAny gastrointestinal condition causing malabsorption or obstruction (e.g. celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome)Xx_NEWLINE_xXMalabsorption condition that would alter the absorption of orally administered medicationsXx_NEWLINE_xXKnown GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXGastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimusXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: History of a malabsorption syndrome or uncontrolled nausea, vomiting, or diarrhea that may interfere with the absorption of oral study medication in the opinion of the investigatorXx_NEWLINE_xXSubject has a known gastrointestinal disorder that in the opinion of the treating investigator is concerning for malabsorption of oral medicationsXx_NEWLINE_xXCurrent evidence of any of the following:\r\n* Uncontrolled hypertension despite addition or adjustment of antihypertensive regimen\r\n* Gastrointestinal disorder affecting absorption\r\n* Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicatedXx_NEWLINE_xXKnown disorder affecting gastrointestinal absorptionXx_NEWLINE_xXPatients must be able to tolerate oral medications and not have gastrointestinal processes that would preclude absorption of olaparibXx_NEWLINE_xXAny history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)Xx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excludedXx_NEWLINE_xXPresence of conditions that will interfere significantly with the absorption of drugsXx_NEWLINE_xXA condition that would interfere with enteric absorptionXx_NEWLINE_xXKnown GI disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing.Xx_NEWLINE_xXGastrointestinal disorder(s) which, in the opinion of the Principal Investigator, would significantly impede the absorption of an oral agent (e.g. active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).Xx_NEWLINE_xXAny gastrointestinal or metabolic condition that could interfere with absorption of oral medicationXx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXPre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparibXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or an unknown reason that may alter the absorption of TAK-228. Patients with enteric stomata are also excluded.Xx_NEWLINE_xXHas malabsorption due to prior gastrointestinal (GI) surgery or GI diseaseXx_NEWLINE_xXGastrointestinal (GI) condition that could interfere with the swallowing or absorption of defactinib.Xx_NEWLINE_xXGastrointestinal diseaseXx_NEWLINE_xXParticipants must not have any clinically significant gastrointestinal abnormalities that in the opinion of the treating investigator may alter absorption of oral medications, such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXGI condition that might limit absorption of oral agentsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide, including difficulty swallowingXx_NEWLINE_xXIncidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing; patients with known GI involvement with mantle cell lymphoma who have no clinical evidence of active disease at the time of enrollment are eligibleXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXGastrointestinal condition that could interfere with the swallowing or absorption of study medicationXx_NEWLINE_xXAny history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXGastrointestinal tract disease or any other reasons resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease or chronic diarrheaXx_NEWLINE_xXAny history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)Xx_NEWLINE_xXMalabsorption syndrome or other conditions that would interfere with intestinal absorptionXx_NEWLINE_xXChronic gastrointestinal illnessXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXLack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome, or the inability to take oral medicationXx_NEWLINE_xXMajor surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption.Xx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowingXx_NEWLINE_xXKnown history of difficulty swallowing, malabsorption or other conditions that may reduce absorption of the product.Xx_NEWLINE_xXPatient has a history of surgery that would interfere with the administration or absorption of the oral study drugsXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXPresence of gastrointestinal disease that would significantly affect compound absorption.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXAny known gastrointestinal disorders which would preclude oral administration of 5-azacitidineXx_NEWLINE_xXInability to swallow oral medication; or the presence of a poorly controlled gastrointestinal disorder that could significantly affect the absorption of oral study drug – e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea (defined as > 4 loose stools per day), malabsorption, or bowel obstruction.Xx_NEWLINE_xXAny known gastrointestinal disorder determined by the investigator that interferes with the absorption of rucaparibXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXGastrointestinal (GI) disorder that negatively affects absorptionXx_NEWLINE_xXKnown dysphagia, short-gut syndrome, gastroparesis, or other condition(s) that limits the ingestion or gastrointestinal absorption of drugs administered orallyXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of study drugs, including difficulty swallowing tablesXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXImpaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallowXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drug, including difficulty swallowing. Gastroesophageal reflux under treatment with proton pump inhibitor or histamine H2 antagonist is allowedXx_NEWLINE_xXCurrent or recent (within 6 months) significant gastrointestinal (GI) disease or condition.Xx_NEWLINE_xXPatients with any severe gastrointestinal or metabolic condition which could interfere with the \r\nabsorption of oral study medications.Xx_NEWLINE_xXSubjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication.Xx_NEWLINE_xXPresence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medicationsXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, patients with enteric stomata are also excluded.Xx_NEWLINE_xXGastrointestinal disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.Xx_NEWLINE_xXPresence of a gastrointestinal condition that may affect drug absorptionXx_NEWLINE_xXGastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinibXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drugXx_NEWLINE_xXAny coexistent medical condition interfering with drug absorptionXx_NEWLINE_xXDifficulty swallowing, malabsorption, known active partial or complete bowel obstruction, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of capecitabineXx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agentXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agentXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agentXx_NEWLINE_xXPatients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXSubjects must have no barriers to taking oral medications, for example uncontrolled nausea, vomiting, diarrhea at baseline, lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndromeXx_NEWLINE_xXMalabsorption condition that would alter the absorption of orally administered medicationsXx_NEWLINE_xXDysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of orally administered drugsXx_NEWLINE_xXGastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment.Xx_NEWLINE_xXPresence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-396.Xx_NEWLINE_xXClinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomyXx_NEWLINE_xXGastrointestinal disorders or abnormalities that would interfere with absorption of the study drugXx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy)Xx_NEWLINE_xXClinically significant gastrointestinal abnormality that would affect the absorption of drug such as gastrointestinal dysfunction, malabsorption syndrome, major resection of the small bowel or total gastrectomy or inflammatory bowel diseaseXx_NEWLINE_xXHistory of malabsorption or other condition that would interfere with absorption of cobimetinib.Xx_NEWLINE_xXPatients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugsXx_NEWLINE_xXPatients with inflammatory bowel disease and/or gastrointestinal (GI) ulcers and/or GI fistulas are eligible but only at the discretion of the study PI after personalized review of their medical history and proximity of SBRT targets to gastrointestinal mucosaXx_NEWLINE_xXCurrent or recent (within 6 months) significant gastrointestinal (GI) disease or condition.Xx_NEWLINE_xXCurrent or recent (within 3 months) gastrointestinal disease that could impact the absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening)Xx_NEWLINE_xXSubjects with significant gastrointestinal abnormalities that may affect absorption (e.g., gastric bypass, short gut syndrome).Xx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug.Xx_NEWLINE_xXAble to swallow and retain oral medication, and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.Xx_NEWLINE_xXFor oral cohorts: The subject has gastrointestinal disease or has had a procedure that is expected to interfere with the oral absorption or tolerance of the study drug (e.g., functionally relevant gastrointestinal obstruction, mucositis/stomatitis, or frequent vomiting).Xx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orallyXx_NEWLINE_xXAble to swallow and retain orally administered medication; does not have any clinically significant gastrointestinal abnormalities, such as malabsorption syndrome or major resection of the stomach or small bowel that may alter absorption of the medicationXx_NEWLINE_xXActive inflammatory gastrointestinal disease or previous gastric resection or lap bandXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study treatment including difficulty swallowingXx_NEWLINE_xXHas presence of a gastrointestinal condition that may affect drug absorptionXx_NEWLINE_xXGastrointestinal abnormalities causing impaired absorption precluding administration of oral medicationsXx_NEWLINE_xXExisting gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease, or previous bowel resection which is considered to be clinically significant or could interfere with absorption.Xx_NEWLINE_xXPrior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)Xx_NEWLINE_xXKnown gastrointestinal disease or gastrointestinal procedure that could interfere with the oral absorption or tolerance of study therapy, including difficulty swallowing.Xx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXFor patients who are treated with oral 5-azacitidine, any gastrointestinal disorder that would interfere with the absorption, distribution, metabolism or excretion of the study drugXx_NEWLINE_xXParticipants with any clinically significant gastrointestinal abnormalities that may alter absorptionXx_NEWLINE_xXGastrointestinal disorder affecting absorption.Xx_NEWLINE_xXPatients who are unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatmentXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXPatients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatmentXx_NEWLINE_xXPresence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of axitinibXx_NEWLINE_xXParticipant must be able to swallow pills and retain oral medication and must not have clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXMalabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of the study drugXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAny condition that may impair the ability to absorb oral medications/investigational product including: prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel; active peptic ulcer disease; and malabsorption syndromeXx_NEWLINE_xXPatient is unable to take drugs orally due to disorders or diseases that may affect gastrointestinal function, such as inflammatory bowel diseases (eg, Crohn’s disease, ulcerative colitis) or malabsorption syndrome, or procedures that may affect gastrointestinal function, such as gastrectomy, enterectomy, or colectomyXx_NEWLINE_xXClinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. For example, subjects should have no more than 50% of the large intestine removed and no sign of malabsorption (e.g. gastrectomy, ileal bypass, chronic diarrhea, Crohn’s disease, malabsorption, gastroparesis).Xx_NEWLINE_xXClinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomyXx_NEWLINE_xXUnable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXGastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease; patients with nasojejunal (NJ), jejunostomy (J) or gastrostomy (G) tube will not be allowed to participateXx_NEWLINE_xXNo gastrointestinal (GI) disorder that negatively affects absorptionXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXGROUP 6: Progressive gastrointestinal disease as defined by all of the following items:\r\n* Disease duration of scleroderma =< 2 years.\r\n* Documented severe malabsorption syndrome requiring nutritional support; severe malabsorption syndrome is > 10% weight loss and on total parenteral nutrition (TPN) or enteral feedings\r\n* High score on distention/ bloating scale (>= 1.60 out of 3.00) on gastrointestinal (GI) questionnaireXx_NEWLINE_xXGastrointestinal abnormalities including but not limited to:Xx_NEWLINE_xXPatients with any condition likely to interfere with absorption of the study medicationXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of MLN0128 or MLN1117. In addition, participants with enteric stomata are also excluded.Xx_NEWLINE_xXActive gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.Xx_NEWLINE_xXHas gastrointestinal abnormalities including:Xx_NEWLINE_xXPatients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, patients with enteric stomata are also excludedXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib, lenalidomide or dexamethasone including difficulty swallowingXx_NEWLINE_xXIncidence of gastrointestinal disease that may significantly alter the absorption of lenalidomideXx_NEWLINE_xXAny contraindication to oral agents or gastrointestinal disorder or procedure which expects to interfere significantly with absorption of protocol treatment.Xx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228; in addition, patients with enteric stomata are also excludedXx_NEWLINE_xXAny history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)Xx_NEWLINE_xXGastrointestinal tract disease or defect or previous history of colitis.Xx_NEWLINE_xXMajor surgery to the upper GI tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorptionXx_NEWLINE_xXAble to tolerate oral medications and no GI illnesses that would preclude absorption of olaparibXx_NEWLINE_xXHistory of gastrointestinal mal-absorption or gastric bypass surgeryXx_NEWLINE_xXUse of medications that alter the absorption or metabolism of levothyroxineXx_NEWLINE_xXActive gastrointestinal (GI) ulceration or hemorrhageXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXClinically active existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohn’s diseaseXx_NEWLINE_xXPrevious bowel resection anticipated to affect drug absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of the study drugs including difficulty swallowingXx_NEWLINE_xXAny condition that impairs the ability to swallow or absorb oral medication (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affective absorption)Xx_NEWLINE_xXGastrointestinal disorders or abnormalities that would interfere with absorption of the study drugXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide including difficulty swallowingXx_NEWLINE_xXPatients with any medical or surgical conditions that would interfere with gastrointestinal absorption of this oral agent are not eligibleXx_NEWLINE_xXSubject has significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentationXx_NEWLINE_xXNo known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac diseaseXx_NEWLINE_xXHistory of gastrointestinal (GI) bleed requiring transfusionXx_NEWLINE_xXGastrointestinal disorder affecting absorptionXx_NEWLINE_xXPatients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatmentXx_NEWLINE_xXKnown gastrointestinal disease or condition that affects the absorption of GT0918.Xx_NEWLINE_xXInability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedureXx_NEWLINE_xXAny clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.Xx_NEWLINE_xXActive gastrointestinal conditions that are expected to impair absorption of orally administered medicationsXx_NEWLINE_xXHave a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agentsXx_NEWLINE_xXGastrointestinal surgery within the previous 3 monthsXx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT: Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of olaparibXx_NEWLINE_xXGastrointestinal abnormalities causing impaired absorption requiring intravenous alimentation, prior surgical procedures affecting absorption including gastric resection, treatment for active peptic ulcer disease in the past 6 months, active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy, malabsorption syndromesXx_NEWLINE_xXSignificant gastrointestinal (GI) disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 751 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)Xx_NEWLINE_xXAbility to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted.Xx_NEWLINE_xXSignificant gastrointestinal condition that could potentially impair the absorption or disposition of the drugXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK228; such as significant chronic diarrhea; in addition, patients with enteric stomata are also excludedXx_NEWLINE_xXHistory of malabsorption or other condition that would interfere with absorption of vemurafenibXx_NEWLINE_xXPatients not able to swallow oral medications or with gastrointestinal conditions that may impact absorption of dasatinibXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128; in addition, patients with enteric stomata are also excludedXx_NEWLINE_xXClinically significant gastrointestinal disease, digestive dysfunction, or surgery that would compromise absorption of oral administration of medicationsXx_NEWLINE_xXGastrointestinal disorder affecting absorptionXx_NEWLINE_xXPatients with gastrointestinal impairment that would affect the absorption of enzalutamide or previous history of colitisXx_NEWLINE_xXSignificant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn’s disease, malabsorption, or grade >= 2 [NCI CTCAE v.4.0] diarrhea of any etiology at screening)Xx_NEWLINE_xXAny gastrointestinal condition causing malabsorption or obstruction (eg, celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome)Xx_NEWLINE_xXPatient has a history of gastrointestinal (GI) surgical procedures, non-surgical procedures or conditions that might interfere with the absorption or swallowing of the study drugsXx_NEWLINE_xXKnown or suspected malabsorption condition or obstructionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, subjects with enteric stomata are also excludedXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorptionXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorptionXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorptionXx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowingXx_NEWLINE_xXSubjects with gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the investigatorXx_NEWLINE_xXHistory or presence of digestive tract diseases, including active gastric/duodenal ulcer or ulcerative colitis, or active hemorrhage of an unresected gastrointestinal tumor, or an evaluation by investigators of having any other condition that could possibly result in gastrointestinal tract hemorrhage or perforation;Xx_NEWLINE_xXInability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product;Xx_NEWLINE_xXAbility to swallow and retain orally-administered medication and does not have any clinically significant gastro-intestinal abnormalities (e.g., malabsorption syndrome or major resection of the stomach or bowel)Xx_NEWLINE_xXPatients with any severe gastrointestinal or metabolic condition that could interfere with absorption of oral medicationsXx_NEWLINE_xXMalabsorption syndrome or other condition that would interfere with intestinal absorption are excludedXx_NEWLINE_xXAny gastrointestinal (GI) disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post major bowel resectionXx_NEWLINE_xXHistory of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP, use of percutaneous endoscopic gastrostomy (PEG) tubesXx_NEWLINE_xXHistory of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMPXx_NEWLINE_xXAny malabsorption condition.Xx_NEWLINE_xXGastrointestinal abnormality that would affect absorption of SGN-2FFXx_NEWLINE_xXAn active gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease, uncontrolled celiac)Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomibXx_NEWLINE_xXKnown gastrointestinal disease or procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac diseaseXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients who have a history of gastrointestinal surgery or other procedures that might in the opinion of the investigator, interfere with the absorption or swallowing of the study drugXx_NEWLINE_xXSigns or symptoms of gastrointestinal obstructionXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agentsXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients must be able to swallow oral medications without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib which are an oral agentXx_NEWLINE_xXSignificant gastrointestinal disorder(s), that could in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 092 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)Xx_NEWLINE_xXA gastrointestinal disorder that may affect the absorption of study medication.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of enzalutamide, including difficulty swallowing tabletsXx_NEWLINE_xXGastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing; patients who have had cystectomy with conduit, neobladder, or pouch using a portion of their terminal ileum are allowed if, the patient is stable without clinically significant metabolic disturbances OR stoma- and/or anastomosis-related complications OR post-surgical gut abnormalities that would compromise drug absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of study drugs, including difficulty swallowing tabletsXx_NEWLINE_xXDifficulty swallowing or malabsorptionXx_NEWLINE_xXLack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to swallowXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXKnown gastro-intestinal disease or gastro-intestinal procedure that could interfere with the oral absorption or tolerance of MLN9708, including difficulty swallowingXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXThe presence of poorly controlled gastrointestinal disorders that could affect the absorption of the afatinib (e.g. Crohn‘s disease, ulcerative colitis, chronic diarrhea, malabsorption)Xx_NEWLINE_xXPatient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drugXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets; diarrhea > Grade 1 despite supportive therapy.Xx_NEWLINE_xXGastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease; patients with nasojejunal (NJ), jejunostomy (J) or gastrostomy (G) tube will not be allowed to participateXx_NEWLINE_xXGastrointestinal disorder or abnormality that would interfere with absorption of the study drugXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAny underlying condition that would significantly interfere with the absorption of an oral medicationXx_NEWLINE_xXImpaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules dailyXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXPresence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugsXx_NEWLINE_xXAny active gastrointestinal (GI) impairment which, in the opinion of the investigator, would impair or alter the absorption of ceritinib (e.g., ulcerative colitis, or Crohn’s disease)Xx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of pazopanib, including (but not limited to) malabsorption syndrome or major resection of the stomach or small bowelXx_NEWLINE_xXConditions leading to inadequate gastrointestinal tract absorption as determined by the treating physician and/or investigatorXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromesXx_NEWLINE_xXAny gastrointestinal condition causing malabsorption or obstruction (eg, celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome)Xx_NEWLINE_xXAble to swallow and retain oral medication, and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHistory of significant difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the tested productXx_NEWLINE_xXPatients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromesXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXActive gastrointestinal (GI) hemorrhage within 2 weeks of study enrollmentXx_NEWLINE_xXActive gastrointestinal (GI) bleed within 2 weeks of study enrollmentXx_NEWLINE_xXUnable to take oral medications or any medical condition that would interfere with the absorption of study medication capsulesXx_NEWLINE_xXGastrointestinal disease that precludes absorptionXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXPatients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugsXx_NEWLINE_xXPatients with impaired gastrointestinal absorption (severe diarrhea or short loop syndromes)Xx_NEWLINE_xXHave a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXInability or unwillingness to swallow INCB054828 or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of INCB054828.Xx_NEWLINE_xXPrior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g, gastric bypass surgery, gastrectomy)Xx_NEWLINE_xXHave gastrointestinal illness or disorder that could affect oral absorption of AP32788 (such as short gut syndrome, Crohn's disease, ulcerative colitis, or CTCAE grade 2 or greater diarrhea of any etiology at baseline).Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or idasanutlin including difficulty swallowingXx_NEWLINE_xXAble to swallow and retain orally-administered medication with no clinically significant gastrointestinal abnormalities that may alter absorptionXx_NEWLINE_xXGastrointestinal abnormalities such as inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection; treatment for active peptic ulcer disease in the past 6 months; active gastrointestinal bleeding as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy; malabsorption syndromesXx_NEWLINE_xXGastrointestinal ailments that may alter the absorption of oral medications (i.e. bowel obstruction, short-gut syndrome)Xx_NEWLINE_xXCurrent or recent (within 6 months) significant gastrointestinal (GI) disease or condition.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXSubjects with an acute gastrointestinal ulcerXx_NEWLINE_xXGastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safetyXx_NEWLINE_xXGastrointestinal diseases or conditions that could affect drug absorptionXx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months, inflammatory bowel disease)Xx_NEWLINE_xXSignificant gastrointestinal abnormalities,Xx_NEWLINE_xXAny underlying condition that would significantly interfere with the absorption of an oral medicationXx_NEWLINE_xXPrior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)Xx_NEWLINE_xXSignificant acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease,malabsorption, or CTCAE Grade ? 2 diarrhea of any etiology.Xx_NEWLINE_xXAbility to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease, or other conditions that may hamper compliance and/or absorption of the study agentXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.Xx_NEWLINE_xXPrior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)Xx_NEWLINE_xXGastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinibXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXInability to swallow or retain oral medications or the presence of active GI disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of vorolanibXx_NEWLINE_xXActive gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.Xx_NEWLINE_xXPre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparibXx_NEWLINE_xXPatient has an inability to swallow oral medications and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. Note: Patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN).Xx_NEWLINE_xXPatients who have gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug are not eligibleXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ibrutinib, including difficulty swallowingXx_NEWLINE_xXGastrointestinal disorder affecting absorptionXx_NEWLINE_xXCurrent or recent (within 3 months of study treatment administration) gastrointestinal disease or conditions that could interfere with the swallowing or absorption of study medication or inability to tolerate oral medicationXx_NEWLINE_xXIncidence of gastrointestinal disease that may significantly alter the absorption of lenalidomideXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.Xx_NEWLINE_xXPatient is able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter drug absorption, such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXClinical evidence of uncontrolled malabsorption and/or any other gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with the absorption of rucaparibXx_NEWLINE_xXPatient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drugXx_NEWLINE_xXAbility to swallow and retain oral medication, with no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHistory or current evidence of malabsorption or liver disease that would impair the absorption of itraconazoleXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXHave a condition that limits the ingestion or absorption of drugs administered by mouthXx_NEWLINE_xXSubjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis).Xx_NEWLINE_xXSubjects with gastrointestinal disorders likely to interfere with absorption of the study medication.Xx_NEWLINE_xXPatients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis), are ineligibleXx_NEWLINE_xXGastrointestinal disorder affecting absorptionXx_NEWLINE_xXSubjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)Xx_NEWLINE_xXActive inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic) or have a history of abdominal surgery or other medical condition that may, in the opinion of the treating physician, interfere with gastrointestinal motility or absorptionXx_NEWLINE_xXUncontrolled serious chronic gastrointestinal condition associated with diarrheaXx_NEWLINE_xXPatients with gastrointestinal disease, or those who have had a procedure that is expected to interfere with the oral absorption or tolerance of BAL101553 (e.g., functionally-relevant gastrointestinal obstruction, or frequent vomiting unresolved upon anti-emetic supportive care), are ineligibleXx_NEWLINE_xXKnown or suspected malabsorption condition or obstructionXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn’s disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or gastrostomy tube (G-tube) administration is not allowedXx_NEWLINE_xXTREATMENT: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn's disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or G-tube administration is not allowedXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXActive gastrointestinal tract disease with malabsorption syndrome or unable to swallow oral medicationsXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXGastrointestinal abnormalities including:\r\n* Inability to take oral medication;\r\n* Requirement for intravenous alimentation;\r\n* Prior surgical procedures affecting absorption including total gastric resection;\r\n* Treatment for active peptic ulcer disease in the past 6 months;\r\n* Active gastrointestinal bleeding as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;\r\n* Malabsorption syndromesXx_NEWLINE_xXGastrointestinal disorders that may interfere with absorption of oral agents, such as malabsorption syndromes; additionally, patients requiring drainage gastrostomy (e.g. percutaneous endoscopic gastrostomy [PEG] tube) and/or parenteral hydration and/or nutrition support are not eligibleXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAny gastrointestinal condition causing malabsorption or obstruction (eg, celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome); unable or unwilling to swallow tablets BIDXx_NEWLINE_xXSubjects with gastrointestinal abnormalities including inability to take oral\n             medication, malabsorption or other conditions like chronic inflammatory bowel disease\n             that may affect absorption.Xx_NEWLINE_xXPatient is able to tolerate oral medications and does not have gastrointestinal illnesses that would preclude absorption of either olaparib or BKM120 or BYL719Xx_NEWLINE_xXPatient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of TRC102Xx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXMust be able to swallow capsules and have no evidence of gastrointestinal (GI) tract abnormality that would alter the absorption of oral medicationsXx_NEWLINE_xXAny underlying condition that would significantly interfere with the absorption of an oral medicationXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowingXx_NEWLINE_xXMalabsorption syndrome or chronic nausea that might hinder absorption and assessment of oral medicationXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAny gastrointestinal disorder with diarrhea as a major symptom, such as Crohn’s, or pre-existing chronic diarrhea Common Terminology Criteria (CTC) grade >= 2 of any etiology; included are malabsorption disorders that in the opinion of the study physician may affect absorption of either afatinib or dasatinibXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients must be able to swallow and retain orally-administered medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHistory of any of the following, unless approval is given by the Protocol Chair:\r\n* Heart disease, including acute myocardial infarction\r\n* Cardiac arrhythmias, including sick sinus syndrome\r\n* Pulmonary disease with a known forced expiratory volume (FEV) of < 1.5 or on oxygen\r\n* Gastrointestinal disease, surgery or malabsorption that could potentially impact the absorption of the study drug\r\n* Patients requiring the use of a feeding tube\r\n* Inability to swallow tabletsXx_NEWLINE_xXPatients unable to swallow orally administered medication at treatment initiation and patients with gastrointestinal disorders likely to interfere with the absorption of the study medicationXx_NEWLINE_xXMalabsorption syndrome or other condition that would interfere with intestinal absorptionXx_NEWLINE_xXPatient must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drugXx_NEWLINE_xXPatients with malabsorption syndrome or other condition that would interfere with intestinal absorptionXx_NEWLINE_xXPatients with gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s, ulcerative colitis)Xx_NEWLINE_xXPatients with any condition that may impair the ability to absorb oral medications/investigational product including:\r\n* Prior surgical procedures affecting absorption including, but not limited to, major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndromeXx_NEWLINE_xXPatient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugsXx_NEWLINE_xXPatients must not have significant gastrointestinal disorders with diarrhea as a major symptom (e.g. Crohn’s disease, malabsorption, etc)Xx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXIs able to swallow and retain orally administered medication and does not have any uncontrolled gastrointestinal (GI) condition such as nausea, vomiting, or diarrhea, or any clinically significant GI abnormalities that may alter absorption such as malabsorption syndromes, hereditary fructose intolerance, glucose-galactose malabsorption, sucrose-isomaltase insufficiency, or major resection of stomach and/or bowelsXx_NEWLINE_xXPatients must not have known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing oral medications per investigator’s clinical judgementXx_NEWLINE_xXPatients must be capable of taking and absorbing oral medications; a patient must be clear of the following:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow tablets\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel\r\n* Active peptic ulcer disease\r\n* Malabsorption syndromeXx_NEWLINE_xXPatients with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:\r\n* Active peptic ulcer disease\r\n* Known gastrointestinal intraluminal metastatic lesions (gastrointestinal serosa metastatic lesions are permitted)\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohn’s disease) or other gastrointestinal conditions with increased risk of perforation\r\n* Patients with clinical symptoms or signs of gastrointestinal obstruction and patients who require parenteral hydration and/or nutritionXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product, including but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXPatients with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orallyXx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and must not have a gastro-intestinal disorder with diarrhea as a major symptom or that may alter absorption such as malabsorption syndromes or gastric resectionXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowel resulting in dumping syndrome or clinical signs of malabsorptionXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of pazopanib, including (but not limited to) malabsorption syndrome or major resection of the stomach or small bowelXx_NEWLINE_xXHistory of bowel obstruction or malabsorption syndromes (within the last 3 months) which might limit the absorption of the study drugXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome, bowel obstruction, or major resection of the stomach or bowelXx_NEWLINE_xXPatients with a bowel obstruction or any other gastrointestinal condition that might affect absorption of the oral drug should be excluded; this would include patients with inability to swallow and retain orally-administered medication, malabsorption syndrome, or those with a major resection of the stomach or bowelsXx_NEWLINE_xXSubject has incidence of gastrointestinal disease that may significantly alter the absorption of LENXx_NEWLINE_xXClinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorptionXx_NEWLINE_xXGastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.Xx_NEWLINE_xXHistory of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the investigational productXx_NEWLINE_xXIs unable to take oral medications, has a history of surgery that would interfere with the administration or absorption of oral medication, has malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that might impair the bioavailability of IPXx_NEWLINE_xXOr any condition that might affect the absorption of orally taken medicationXx_NEWLINE_xXGastrointestinal (GI) condition that interferes with drug absorptionXx_NEWLINE_xXPatients who have known gastrointestinal (GI) disease or GI procedures which could interfere with the oral absorption or tolerance of alisertib are not eligible; examples include (but are not limited to) partial gastrectomy, history of small intestine surgery, and celiac diseaseXx_NEWLINE_xXGastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.Xx_NEWLINE_xXGastrointestinal disorder affecting absorption;Xx_NEWLINE_xXPatients are excluded if they have known involvement of melanoma within the gastrointestinal tractXx_NEWLINE_xXHistory of gastrointestinal disorders that may interfere with the absorption of study drug (including gastric bypass surgery)Xx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXPresence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn’s disease or chronic pancreatitis)Xx_NEWLINE_xXHave malabsorption syndrome or other gastrointestinal (GI) illness or condition.Xx_NEWLINE_xXAny malabsorption condition.Xx_NEWLINE_xXSignificant gastrointestinal disorder(s) (e.g., active Crohn's disease or ulcerative colitis, or a history of extensive gastric resection and/or small intestinal resection) such that absorption of oral medications is impaired.Xx_NEWLINE_xXSignificant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection and small intestinal resection).Xx_NEWLINE_xXGastrointestinal tumors, tumors that have originated or metastasized to the liver, or other tumors known to interfere with the absorption, distribution, metabolism, or excretion of drugs.Xx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXGastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease; patients with nasojejunal (NJ), jejunostomy (J) or gastrostomy (G) tube will not be allowed to participateXx_NEWLINE_xXHistory of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.Xx_NEWLINE_xXHistory of gastrointestinal condition that may affect drug absorption.Xx_NEWLINE_xXknown gastrointestinal disease or condition which may affect the absorption of ASN003;Xx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of everolimus, MLN0128, or MLN1117. In addition, participants with enteric stomata are excluded.Xx_NEWLINE_xXInability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of lenvatinib or midazolam.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or procedure that could interfere with the GI absorption or tolerance of bicalutamide, including difficulty swallowing oral medications.Xx_NEWLINE_xXMalabsorption syndrome or poor upper gastrointestinal integrityXx_NEWLINE_xXSignificant gastrointestinal disorder(s) (e.g., active Crohn's disease or ulcerative colitis, or a history of extensive gastric resection and/or small intestinal resection) such that absorption of oral medications is impaired.Xx_NEWLINE_xXAny malabsorption condition.Xx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery with significant removal of the small intestine, and celiac diseaseXx_NEWLINE_xXGastrointestinal tract disease or defect with associated malabsorption syndromeXx_NEWLINE_xXGastrointestinal disorders or abnormalities that would interfere with absorption of the study drugXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXSignificant or recent acute gastrointestinal disorders with diarrhea as a major symptom.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowingXx_NEWLINE_xXAny current or recent (within 3 months) gastrointestinal disease that could potentially impact the ability to swallow and/or absorb study drug (i.e., gastrointestinal surgery, malabsorption syndrome)Xx_NEWLINE_xXPre-existing duodental stent and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of study drug.Xx_NEWLINE_xXGastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigatorXx_NEWLINE_xXKnown gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of CUDC-907.Xx_NEWLINE_xXInability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowelXx_NEWLINE_xXImpairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.Xx_NEWLINE_xXInability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medicationsXx_NEWLINE_xXPatients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)Xx_NEWLINE_xXPre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drugXx_NEWLINE_xXGastrointestinal disorders or abnormalities that would interfere with absorption of the study drugXx_NEWLINE_xXActive gastrointestinal conditions that are expected to impair absorption of orally administered medicationsXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXUnable to swallow oral medications, or has gastrointestinal condition deemed to jeopardize intestinal absorption.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXAny clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.Xx_NEWLINE_xXPatients must not have gastrointestinal tract disease resulting in an inability to take oral or enteral medication via a feeding tube or a requirement for intravenously (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer diseaseXx_NEWLINE_xXSubject has a gastrointestinal disorder affecting absorption.Xx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128Xx_NEWLINE_xXGastrointestinal (GI) hemorrhage (active or in recent 6 months)Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib (ixazomib citrate) including difficulty swallowingXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXPatients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXAny gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomitingXx_NEWLINE_xXSubjects who had major surgery to the upper gastrointestinal tract, or who have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption.Xx_NEWLINE_xXAny gastrointestinal disorder expected to limit absorption of ibrutinibXx_NEWLINE_xXInability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowelXx_NEWLINE_xXAny medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)Xx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXGastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drugXx_NEWLINE_xXPatients with gastrointestinal comorbidities that would affect intake or absorption of ponatinibXx_NEWLINE_xXGastrointestinal disorders or abnormalities that would interfere with absorption of the study drug; patients who are unable to orally swallow the study medicationXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac diseaseXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXAny clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels as well as subjects with ulcerative colitis are also excludedXx_NEWLINE_xXManifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown or other reason that may alter the absorption of MLN0128.Xx_NEWLINE_xXAny underlying condition that would significantly interfere with the absorption of an oral medicationXx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain X-82 tablets are excludedXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXGastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapyXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 or pomalidomide including difficulty swallowingXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXGastrointestinal disease, surgery or malabsorption that could potentially impact the absorption of the study drugXx_NEWLINE_xXHave malabsorption syndrome or other GI illness that could affect oral absorption of the study drug.Xx_NEWLINE_xXPatients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugsXx_NEWLINE_xXSubjects with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.Xx_NEWLINE_xXGastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.Xx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)Xx_NEWLINE_xXActive gastrointestinal tract disease with malabsorption syndromeXx_NEWLINE_xXPatients with impairment of gastrointestinal function that may alter the absorption of BKM120Xx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of oral study drug(s) within 3 months of enrollmentXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drugXx_NEWLINE_xXSignificant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agentXx_NEWLINE_xXSignificant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agentXx_NEWLINE_xXSignificant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agentXx_NEWLINE_xXClinically significant gastrointestinal disorders that may interfere with absorption of drugXx_NEWLINE_xXPrior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)Xx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorption Exclusion Criteria Related to Medications:Xx_NEWLINE_xXInability to swallow pills or any significant gastrointestinal diseases, which would preclude adequate absorption of oral medications.Xx_NEWLINE_xXCurrent disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.Xx_NEWLINE_xXGastrointestinal abnormalities including:\r\n* Inability to take oral medications\r\n* Requirement for intravenous alimentation\r\n* Prior surgical procedure affecting absorption including total gastric resection\r\n* Treatment for active peptic ulcer disease in the past 6 months\r\n* Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy\r\n* Malabsorption syndromeXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHave a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXPatients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of GSK1120212 and GSK2141795Xx_NEWLINE_xXPresence of active gastrointestinal (GI) disease or other condition that could affect gastrointestinal absorption (e.g. malabsorption syndrome) or predispose a subject to GI ulceration; subjects with prior Whipple procedure are eligibleXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXAble to swallow and retain orally administered medication. NOTE: Subject should not have any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. For example, subjects should have no more than 50% of the large intestine removed and no sign of malabsorption (i.e., diarrhea).NOTE: If clarification is needed as to whether a condition will significantly affect the absorption of study treatments, contact the GSK Medical Monitor.Xx_NEWLINE_xXClinically significant GI abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. For example, subjects should have no more than 50% of the large intestine removed and no sign of malabsorption (i.e., diarrhea)Xx_NEWLINE_xXMalabsorption syndrome or other conditions that would interfere with intestinal absorptionXx_NEWLINE_xXRefractory gastrointestinal (GI) disease that would prevent absorption of oral agentsXx_NEWLINE_xXPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.Xx_NEWLINE_xXSignificant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn’s disease, malabsorption, or grade >= 2 diarrhea of any etiology screening)Xx_NEWLINE_xXNo gastrointestinal (GI) disorder that negatively affects absorptionXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drugXx_NEWLINE_xXHave a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXPART B: Patients with inability to take oral medications, or, in the investigator’s opinion, gastrointestinal conditions or abnormalities likely to influence the absorption of oral medicationsXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: \r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel\r\n* Presence of uncontrolled infection\r\n* Corrected QT interval (QTc) > 480 msecs using Bazett’s formulaXx_NEWLINE_xXHistory of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (for example, Crohn’s disease, ulcerative colitis); patients requiring feeding tubes are permittedXx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)Xx_NEWLINE_xXSubjects with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.Xx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients must be able to retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels; patients who have feeding tubes can enroll in the study provided that the capsules do not need to be modifiedXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugXx_NEWLINE_xXClinically significant gastrointestinal disorders that may interfere with absorption of drug.Xx_NEWLINE_xXInability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedureXx_NEWLINE_xXGastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.Xx_NEWLINE_xXAny gastrointestinal disease that could hinder the absorption of enzalutamideXx_NEWLINE_xXAny gastrointestinal disease that could hinder the absorption of enzalutamideXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXThe patient is unable to swallow pills or diagnosed with a gastrointestinal disorder that are likely to interfere with the absorption of the study drug or with the patient’s ability to take regular oral medicationXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome or\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXPatients with any condition of the gastrointestinal tract that is expected to result in an inability to swallow or absorb oral medications (i.e. prior surgical procedures affecting absorption and requiring intravenous [I.V.] alimentation); this will be determined at the discretion of the principal investigator (PI)Xx_NEWLINE_xXMalabsorption problem that may limit or inhibit the absorption of MEK162Xx_NEWLINE_xXLack of physical integrity of the upper gastrointestinal tract or malabsorption syndromeXx_NEWLINE_xXHistory of gastrointestinal disorder or prior extensive gastrointestinal surgery that may interfere with sufficient absorption of the study compounds.Xx_NEWLINE_xXHave a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXPresence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugsXx_NEWLINE_xXHistory of GI perforation within 12 months prior to registration or presence of active GI disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugsXx_NEWLINE_xXGastrointestinal condition which could impair absorption of study medicationXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXSignificant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g. Crohn's disease, ulcerative colitis, extensive gastric resection)Xx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients with any of the following conditions or complications are NOT eligible for participation:\r\n* Uncontrolled hypertension\r\n* Known hypersensitivity to ergot derivatives\r\n* History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve (to be determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis)\r\n* History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders\r\n* Gastrointestinal (GI) tract disease resulting in an inability to take oral medication\r\n* Malabsorption syndrome\r\n* Require intravenous (IV) alimentation\r\n* History of prior surgical procedures affecting absorption\r\n* Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)Xx_NEWLINE_xXPatient must not have any clinically significant abnormality that may affect absorption of investigational product including, but not limited to, malabsorption syndrome or major resection of the stomach or small bowelXx_NEWLINE_xXRefractory nausea or vomiting, malabsorption, external biliary shunt, or history of any type of gastrointestinal surgery that would preclude adequate absorption of study drugXx_NEWLINE_xXPresence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugsXx_NEWLINE_xXNo known gastrointestinal (GI) pathology that would interfere with drug bioavailabilityXx_NEWLINE_xXSignificant gastrointestinal disorders that may interfere with absorption of tosedostat.Xx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain sunitinib tablets are excludedXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowel and experiencing the “dumping” syndromeXx_NEWLINE_xXLack of physical integrity of the upper gastrointestinal tract or malabsorption syndromeXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXAny known gastrointestinal disorders which would preclude oral administration of 5-azacitidineXx_NEWLINE_xXContinued ability to swallow and retain orally administered study treatment(s) and does not have any clinically significant GI abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXCircumstances likely to interfere with absorption of orally administrated drugs.Xx_NEWLINE_xXLack of physical integrity of the upper gastrointestinal tract or malabsorption syndromeXx_NEWLINE_xXPatients unable to take oral drugs or with known malabsorption syndromesXx_NEWLINE_xXHistory of any disease that could lead to impaired absorption of drugsXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: \r\n* Malabsorption syndrome \r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowingXx_NEWLINE_xXContinued ability to swallow and retain orally administered study treatment(s) and does not have any clinically significant GI abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXDiarrhea ? Grade 2, impaired gastrointestinal absorptionXx_NEWLINE_xXPresence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK medical monitor for guidance to enrol the subject;Xx_NEWLINE_xXGastrointestinal abnormalities including:\r\n* Inability to take oral medication\r\n* Requirement for intravenous alimentation\r\n* Prior surgical procedures affecting absorption including gastric resection\r\n* Treatment for active peptic ulcer disease in the past 6 months\r\n* Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy\r\n* Malabsorption syndromesXx_NEWLINE_xXGastrointestinal disease that would impact on drug absorptionXx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXMalabsorption syndrome, (prior surgical procedures affecting absorption), or inflammatory gastrointestinal (GI) disease (e.g., Crohn’s, ulcerative colitis) which in the opinion of the study coordinator is likely to limit normal absorption of the drugXx_NEWLINE_xXPatients must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXContinued ability to swallow and retain orally administered study drug(s) and does not have any clinically significant GI abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXHave malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinibXx_NEWLINE_xXPatients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugsXx_NEWLINE_xXSignificant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)Xx_NEWLINE_xXPatients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis), therefore could affect the absorption of AMG 232 at the discretion of treating physicianXx_NEWLINE_xXGastrointestinal (GI) tract disease that causes an inability to take oral medication, malabsorption syndrome, or a requirement for IV alimentation; prior surgical procedures affecting absorption; or uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)Xx_NEWLINE_xXInability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medicationsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption of study medication including difficulty swallowingXx_NEWLINE_xXGastrointestinal disease that interferes with receipt of oral drugs;Xx_NEWLINE_xXPatients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparibXx_NEWLINE_xXAny clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet formXx_NEWLINE_xXHistory of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (eg, Crohn’s disease, ulcerative colitis); patients requiring feeding tubes are permittedXx_NEWLINE_xXMalabsorption due to prior gastrointestinal (GI) surgery, GI diseaseXx_NEWLINE_xXGastrointestinal disease that would impact on drug absorptionXx_NEWLINE_xXPresence of surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drugXx_NEWLINE_xXHistory of gastrointestinal diseaseXx_NEWLINE_xXGastrointestinal conditions that could affect drug absorption including post surgical states such as gastric bypassXx_NEWLINE_xXHistory of gastrointestinal disease with diarrhea as the major symptom.Xx_NEWLINE_xXAny malabsorption conditionsXx_NEWLINE_xXSubject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.Xx_NEWLINE_xXKnown gastrointestinal disease or condition that affects the absorption of ASN001, or difficulty swallowing large capsules.Xx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPatients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorptionXx_NEWLINE_xXGastrointestinal disease that may interfere with drug absorption.Xx_NEWLINE_xXAny malabsorption condition which, in the opinion of the treating physician, will affect the absorption of any of the agents used in this study.Xx_NEWLINE_xXSignificant active gastrointestinal disease that might impair absorption of study therapy;Xx_NEWLINE_xXAble to swallow and retain orally administered study treatment and does not have any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.Xx_NEWLINE_xXGastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.Xx_NEWLINE_xXSubject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac diseaseXx_NEWLINE_xXHas inability to swallow oral medications or presence of a gastrointestinal disorder (e.g. malabsorption) deemed to jeopardize intestinal absorption of MK-8628Xx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease) within last 3 monthsXx_NEWLINE_xXGastrointestinal (GI) condition that could interfere with the swallowing or absorption of study medicationXx_NEWLINE_xXGastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.Xx_NEWLINE_xXGastrointestinal disorders that may significantly interfere with absorption of study drugXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months).Xx_NEWLINE_xXHistory of malabsorption or other condition that would interfere with absorption of vemurafenib/cobimetinibXx_NEWLINE_xXAn upper gastrointestinal or other condition that would impair swallowing or absorption of oral medicationXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug as determined by the investigatorXx_NEWLINE_xXImpairment of gastrointestinal function or gastrointestinal disease that may alter the absorption of sunitinib.Xx_NEWLINE_xXActive gastrointestinal (GI) conditions that might predispose to drug intolerance or poor drug absorptionXx_NEWLINE_xXGastrointestinal condition which could interfere with the swallowing or absorption of study drug.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that is expected to interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing; as determined by the investigatorXx_NEWLINE_xXAny underlying condition that would significantly interfere with the absorption of an oral medicationXx_NEWLINE_xXPatients who cannot take oral medication, require intravenous alimentation, had prior surgical procedures affecting gastrointestinal absorption, or have active peptic ulcer diseaseXx_NEWLINE_xXSignificant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g. Crohn's disease, ulcerative colitis, malabsorption or Common Toxicity Criteria (CTC) grade >= 2 diarrhea of any etiologyXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXMajor gastrointestinal (GI) disease as defined but not limited to the following: history of inflammatory bowel disease or other illness resulting in chronic diarrhea, known achlorhydria or history of GI surgery that could reduce the acidity of the stomach, acute pancreatitis or cholecystitis within 6 months prior to Baseline, or GI disease that may interfere with the absorption of orally-administered drugs.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowingXx_NEWLINE_xXHistory of gastrointestinal condition that might interfere with drug absorptionXx_NEWLINE_xXHistory of any disease that could lead to impaired absorption of drugsXx_NEWLINE_xXPresence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.Xx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational productsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficultyXx_NEWLINE_xXPersistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorptionXx_NEWLINE_xXAny major surgery or gastrointestinal disease that would interfere with administration of oral medicationsXx_NEWLINE_xX2. GI condition that could interfere with the swallowing or absorption of study drug.Xx_NEWLINE_xXGastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.Xx_NEWLINE_xXPatients with significant gastrointestinal disorder that, in the opinion of the investigator, could interfere with absorption of quinacrine and/or erlotinib (eg, Crohn’s disease, small or large bowel resection, malabsorption syndrome)Xx_NEWLINE_xXAny condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption) that impairs patients ability to swallow MK-2206 tabletsXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product.Xx_NEWLINE_xXGastro-intestinal abnormalities that could affect the absorption of study drug.Xx_NEWLINE_xXA history of malabsorption or other condition that would interfere with absorption of vemurafenib or cobimetinib.Xx_NEWLINE_xXPatients with gastrointestinal (GI) absorptive problems making it unlikely to absorb study medication or more likely to experience GI toxicitiesXx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain tablets are excludedXx_NEWLINE_xXPatient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of terameprocolXx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXPatients with conditions that would prevent absorption of the study drugXx_NEWLINE_xXGastrointestinal disorder affecting absorption.Xx_NEWLINE_xXPresence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.Xx_NEWLINE_xXHistory of malabsorption or other condition that would interfere with enteral absorptionXx_NEWLINE_xXGastrointestinal condition which could impair absorption of study medicationXx_NEWLINE_xXMalabsorption syndrome or other condition that would interfere with enteric absorptionXx_NEWLINE_xXClinically significant gastrointestinal abnormality that would affect absorption of the drugXx_NEWLINE_xXPatients with impaired gastrointestinal absorption (severe diarrhea or short loop syndromes)Xx_NEWLINE_xXGastrointestinal FunctionXx_NEWLINE_xXAny clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXGastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of CUDC-907; this includes uncontrolled diarrhea (> 1 watery stool/day), major abdominal surgery, significant bowel obstruction and/or gastrointestinal diseases that could alter the assessment of pharmacokinetics or safety, including but not limited to: irritable bowel syndrome, ulcerative colitis, Crohn’s disease and hemorrhagic coloproctitisXx_NEWLINE_xXParticipants with gastrectomy or pre-existing gastrointestinal disorders that may interfere with the proper absorption of the drug(s), as per conclusion of the clinical InvestigatorXx_NEWLINE_xXInability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatmentXx_NEWLINE_xXSubject has significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentation.Xx_NEWLINE_xXAny gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomitingXx_NEWLINE_xXKnown dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orallyXx_NEWLINE_xXSignificant or recent acute gastrointestinal disorders with diarrhea as a major symptom for example Crohn's disease, malabsorption or Common Terminology Criteria (CTC) grade >= 2 diarrhea of any etiologyXx_NEWLINE_xXHistory of gastrointestinal disorder or defect. Impaired ability to swallow oral medication. Persistent diarrhea or malabsorption.Xx_NEWLINE_xXPatients with gastrointestinal (GI) tract disease, causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)Xx_NEWLINE_xXImpaired GI function or GI disease that may interfere with absorption of AZD8835 or patients unable to take oral medicationXx_NEWLINE_xXPatients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea or other gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXRecurrent nausea and/or vomiting within 14 days before the first dose of alisertib or known gastrointestinal (GI) abnormality or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib. Examples include, but are not limited to, disease-related bowel obstruction, pancreatic insufficiency, use of pancreatic enzymes, a gastric condition (such as severe reflux or active peptic ulcer disease) that requires chronic and uninterrupted use of proton pump inhibitors, partial gastrectomy, history of small intestine surgery, and celiac disease.Xx_NEWLINE_xXAny history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drugXx_NEWLINE_xXGastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent.Xx_NEWLINE_xXGastrointestinal disorders or abnormalities that would interfere with absorption of study drugXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of fluconazole or itraconazole including difficulty swallowing capsules.Xx_NEWLINE_xXPatients unable to take oral drugs (e.g. lack of physical integrity of the upper gastrointestinal [GI] tract or known malabsorption syndromes)Xx_NEWLINE_xXPatients with malabsorption syndrome or other condition that would interfere with intestinal absorption or ability to swallow oral medicationXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXAny gastrointestinal disorder with diarrhea as a major symptom, such as Crohn's, or pre- existing chronic diarrhea CTCAE Grade ? 2 of any etiology. Included are malabsorption disorders or surgical procedures that in the opinion of the investigator may affect absorption of study drug;Xx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXPresence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.Xx_NEWLINE_xXMajor surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorptionXx_NEWLINE_xXKnown impairment of gastrointestinal function that would alter drug absorption.Xx_NEWLINE_xXThe subject has difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the trial drug. Subjects requiring total parenteral nutrition are to be excluded.Xx_NEWLINE_xXGastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.Xx_NEWLINE_xXImpairment of GI function or GI disease that could interfere with the absorption of AEB071 or everolimus.Xx_NEWLINE_xXHistory of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.Xx_NEWLINE_xXHave a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of orteronel, including difficulty or inability to swallow tabletsXx_NEWLINE_xXAble to swallow and retain orally administered study treatment and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXClinically significant gastrointestinal abnormalities, apart from gastric cancer, including uncontrolled inflammatory gastrointestinal diseasesXx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excludedXx_NEWLINE_xXGastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.Xx_NEWLINE_xXSignificant gastrointestinal disorder(s), (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection) such that, in the opinion of the treating investigator, absorption of oral medications may be impaired.Xx_NEWLINE_xXPresence of any clinically significant gastrointestinal (GI) abnormality or other condition(s) that may alter absorption such as malabsorption syndrome or major resection of the stomach or substantial portion of the small intestineXx_NEWLINE_xXAble to swallow and retain enterally (per oral [PO] or nasogastric or gastric tube) administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.Xx_NEWLINE_xXPresence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption of drugs.Xx_NEWLINE_xXAny malabsorption conditionXx_NEWLINE_xXPatients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow, retain, and/or absorb the drug are excludedXx_NEWLINE_xXAny condition that impairs ability to swallow pills (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease)Xx_NEWLINE_xXPrior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drugXx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pillsXx_NEWLINE_xXPatients with gastrointestinal disorders or abnormalities that would interfere with absorption of study treatment.Xx_NEWLINE_xXInability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowelXx_NEWLINE_xXHistory of malabsorption or other condition that would interfere with enteral absorptionXx_NEWLINE_xXInability to absorb abiraterone after oral administration (i.e., previous major gastrointestinal surgery or gastrointestinal disease resulting in malabsorption)Xx_NEWLINE_xXPatients with a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentsXx_NEWLINE_xXMalabsorption ;Xx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXHistory of gastrointestinal (GI) hemorrhageXx_NEWLINE_xXKnown gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption, or tolerance of IXAZOMIBXx_NEWLINE_xXClinically significant GI abnormalities that may affect absorption of investigational product.Xx_NEWLINE_xXIncidence of gastrointestinal disease that may significantly alter the absorption of pomalidomideXx_NEWLINE_xXSignificant gastrointestinal disorder(s), in the opinion of the investigator, that may influence drug absorptionXx_NEWLINE_xXg.i. condition that would prevent ingestion or absorption of 5-FCXx_NEWLINE_xXgastrointestinal impairment or disease that may interfere with drug absorptionXx_NEWLINE_xXPresence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of drugs.Xx_NEWLINE_xXHistory of malabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXAny gastrointestinal disorders which may interfere with the absorption of oseltamivirXx_NEWLINE_xXAny gastrointestinal disorder expected to limit absorption of ibrutinibXx_NEWLINE_xXInability or unwillingness to swallow oral medication; manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption; in addition, patients with enteric stomata are also excludedXx_NEWLINE_xXPresence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption) (e.g. malabsorption syndrome, history of biliary tract disease)Xx_NEWLINE_xXSubject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.Xx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXOngoing gastrointestinal medical condition such as Crohn’s disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medicationXx_NEWLINE_xXAny underlying condition that would significantly interfere with the absorption of an oral medicationXx_NEWLINE_xXPatients must be capable of taking and absorbing oral medications; a patient must be clear of the following: any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow tablets; prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel; active peptic ulcer disease; malabsorption syndromeXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: malabsorption syndrome; major resection of the stomach or small bowelXx_NEWLINE_xXClinically significant gastrointestinal abnormalities that may affect absorption (e.g. malabsorption syndrome, major resection of the stomach or small bowel)Xx_NEWLINE_xXGastrointestinal conditions that may significantly affect the absorption of regorafenibXx_NEWLINE_xXAble to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXGastrointestinal disorders that would interfere with drug absorptionXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agentXx_NEWLINE_xXSubjects with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs the ability to swallow and retain enzalutamide are excludedXx_NEWLINE_xXEvidence of >= grade 2 gastrointestinal toxicity (including, but not limited to: nausea, vomiting, anorexia, gastrointestinal pain)Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659.Xx_NEWLINE_xXMalabsorption syndrome or other condition that would interfere with enteral absorptionXx_NEWLINE_xXGastrointestinal disorder affecting absorption.Xx_NEWLINE_xXGastrointestinal disorder affecting absorption.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets or diarrhea >Grade 1 despite supportive therapy.Xx_NEWLINE_xXGastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimusXx_NEWLINE_xXGastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drugXx_NEWLINE_xXActive uncontrolled stage 3-4 acute gastrointestinal (GI) GVHD prior to administration of ibrutinibXx_NEWLINE_xXPATIENT: Diagnosis of lung or gastrointestinal (GI) (colorectal, pancreas, liver) cancersXx_NEWLINE_xXSubjects with gastrointestinal conditions which might result in malabsorption of the study drugXx_NEWLINE_xXPatients with irritable bowel syndrome, Crohn's disease, or other clinically significant gastrointestinal (GI) related condition that might confound the VEGF-TKI-related-diarrhea endpointXx_NEWLINE_xXKnown upper gastrointestinal (UGI) tract obstruction precluding ERC.Xx_NEWLINE_xXGastrointestinal obstruction or an active peptic ulcerXx_NEWLINE_xXGastrointestinal disorders in the opinion of the treating physician that would impair absorptionXx_NEWLINE_xXImpaired gastrointestinal absorptionXx_NEWLINE_xXHistory of clinically-significant gastrointestinal (GI) disease; GI perforation within 1 year; GI bleeding or acute pancreatitis within 3 months; or diverticulitis within 4 weeks of first study drug administrationXx_NEWLINE_xXHistory of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-002AXx_NEWLINE_xXActive peptic ulcer disease or evidence of gastrointestinal bleedXx_NEWLINE_xXPatients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromesXx_NEWLINE_xXHave a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of ranolazineXx_NEWLINE_xXMedical contraindications to undergoing endoscopy or obstruction of the gastrointestinal (GI) tract that precludes passage of the endoscopeXx_NEWLINE_xXGastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medicationsXx_NEWLINE_xXIndividuals with prior gastric bypass surgery or procedure that would impair absorption of nutrientsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXPatients with known gastrointestinal conditions that could potentially interfere with absorption of orally administered medicationsXx_NEWLINE_xXGastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease; patients with nasogastric (NG)-tube, jejunostomy feeding (J)-tube, or gastrostomy (G)-tube will not be allowed to participateXx_NEWLINE_xXPatients with any of the following conditions or complications are NOT eligible for participation:\r\n* Gastrointestinal (GI) tract disease resulting in an inability to take oral medication\r\n* Malabsorption syndrome\r\n* Require intravenous (IV) alimentation\r\n* History of prior surgical procedures affecting absorption\r\n* Uncontrolled inflammatory GI disease (e.g., Crohn’s, ulcerative colitis)Xx_NEWLINE_xXIndividuals with any history of transfusion-dependent gastrointestinal bleeding, gastrointestinal perforation or gastrointestinal obstruction; if any of these events had been due to a malignancy of the GI tract and the malignancy has since been removed, the patient is eligibleXx_NEWLINE_xXPatients with known manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228) are ineligibleXx_NEWLINE_xXAble to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXParticipants unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medicationXx_NEWLINE_xXPatients must not have clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:\r\n* Malabsorption syndrome\r\n* Major resection of the stomach or small bowelXx_NEWLINE_xXHistory of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of orally administered hormonal agentsXx_NEWLINE_xXActive difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions (including pancreas deficiency requiring Creon therapy) that may hamper compliance and/or absorption of M3541Xx_NEWLINE_xXActive gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.Xx_NEWLINE_xXHistory or current evidence of gastrointestinal malabsorption which, in the opinion of the investigator, may affect the extent of absorption of pritelivir.Xx_NEWLINE_xXActive inflammatory gastrointestinal disease or previous gastric resection or lap bandXx_NEWLINE_xXPatients with a diverting ileostomy, with a history of inflammatory bowel disease, familial adenomatous polyposis (FAP), or active gastrointestinal (GI) symptoms (gastrointestinal bleed, diarrhea, severe abdominal pain, etc.)Xx_NEWLINE_xXPatients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of AZD1775 (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease); Note: patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN)Xx_NEWLINE_xXInability to take oral medication, or presence of a malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability of H3B-6527. Participants with prior gastric resection are eligibleXx_NEWLINE_xXHistory or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolismXx_NEWLINE_xXHistory of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric absorptionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowingXx_NEWLINE_xXHistory of Crohn's disease, celiac sprue or other malabsorption syndrome which may interfere with digestion and absorption of broccoli sprout extractXx_NEWLINE_xXAble to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowelsXx_NEWLINE_xXGastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)Xx_NEWLINE_xXKnown gastrointestinal (GI) abnormality (including recurrent nausea or vomiting) or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib.Xx_NEWLINE_xXHistory of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect the absorption of kavaXx_NEWLINE_xXPatients who had prior major gastrointestinal surgery removing part of gastrointestinal tract and/or gall bladder.Xx_NEWLINE_xXCurrently active gastrointestinal (GI) disease, or prior surgery that may affect ability to absorb oral medicationsXx_NEWLINE_xXKnown gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of the TAK-580.Xx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659, including difficulty swallowing tablets or diarrhea greater than (>) Grade 1 despite supportive therapy.Xx_NEWLINE_xXSuspicion or known history of gastrointestinal obstructionXx_NEWLINE_xXKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets; diarrhea >Grade 1 despite supportive therapy.Xx_NEWLINE_xXPresence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.Xx_NEWLINE_xXMajor surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorptionXx_NEWLINE_xXGastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug.Xx_NEWLINE_xX